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QUANT1CYT: KARYOMETRIC ANALYSIS OF 
BLADDER WASHING FOR PATIENTS WITH SUPERFICIAL 
BLADDER CANCER
H. G. VAN DER POEL, J. A. WITJES, P. v a n  STRATUM, M. E. BOON, F. M. J. DEBRUYNE,
a n d  J. A. SCHALKEN
ABSTRACT
Objectives. Quantitative cytology by image-analysis techniques enables objective interpretation of nuclear 
features in light microscopic images. QUANTICVT, a quantitative karyometric cytology system, was used in 
the follow-up of patients with superficial bladder cancer.
Methods. From 1992 to 1995, 41 37 samples from 1412 patients were obtained. At 1 -year follow-up 
after the initial bladder washing, a tumor recurrence rate of 21% was found. In this period, tumor 
progression to invasive disease occurred in 1.6% of patients. Scoring of tumor by the QUANTICYT 
system was based on two nuclear features: the 2c deviation index and the mean of a nuclear shape 
feature: MPASS.
Results. The method was found to be reproducible and superior to visual cytologic interpretation. QUAN­
TICYT analysis of the bladder washings resulted in a score of low, intermediate, and high risk. In a multivariate 
analysis, highest grade of earlier tumor and QUANTICYT risk score were the best predictors of tumor recur­
rence and progression. For the easy application of QUANTICYT analysis in daily routine, a report form that 
included patient history and DNA histogram was developed.
Conclusions. QUANTICYT karyometric analysis of bladder-wash material proved a useful, clinically applicable 
grading tool in the follow-up of patients with superficial bladder cancer, with sufficient power to be used in 
decision-making in the individual patient. UROLOGY 48: 357-364, 1996.
I n approximately 66% to 80% of patients with 
bladder cancer, the disease starts as a super­
ficial (tha t is, noninvasive) lesion in the blad­
der m ucosa.1,2 These so-called Ta and T1 tu­
mors show a tendency to recur in 30% to 60% 
of patients during follow-up after treatment of 
the primary tumor.2“4 Moreover, 15% of pa­
tients finally suffer invasive, often lethal, forms 
of bladder cancer.5
In recent years, clinical markers for the pre­
diction of prognosis have been studied.2,3 Mul­
tiple and early recurrent cancers showed a high 
tendency to progress to invasive disease.3 Kurth 
et a l 3 presented a table for relative progression-
From the Department o f Urology, University Hospital, Nijme­
gen, The Netherlands; and Leiden Cytology and Pathology Lab­
oratory , Leiden, The Netherlands 
Reprint requests: J.A. Schalken, M.D., Department o f Urology, 
P.O. Box 9101, 6500 HB Nijmegen , The Netherlands 
Submitted: April 17,1996, accepted (with  revisions): May 14,
1996
C opyright  1996 by Elsevier Scien ce  In c .
ALL RIGHTS RESERVED
risk estimation using tumor grade, tumor size, 
and early recurrence rate. Relative risk values for 
progression ranged from 0 in small (less than 1.5 
cm) G1 tumors with a recurrence rate per year 
of less than 1, to 3.7 in large (greater than 3.0 
cm) G3 cancers that were frequently recurrent 
(more than three times per year) .3 Patients were 
divided into three risk groups; 3-year progres­
sion rates per group were 7%, 16%, and 31% re­
spectively.3
The follow-up of patients with superficial blad­
der cancer is done by cystoscopy and cytology. 
Hall et al.6 proposed a follow-up scheme based on 
the initial clinical prognostic findings as found by 
Kurth et a l 3 Cystoscopy frequency in patients at 
low risk for tumor progression could be signifi­
cantly reduced.6 So far, however, these recom­
mendations have not been applied on a wide 
scale.
However, even in the low-risk group of patients 
(as defined by Kurth et a l 3) , 7% of tumors still 
progress to invasive disease within 3 years after
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diagnosis; this group comprised 52% of their pa­
tient population, whereas the high-risk group 3 
comprised only 6.7% of the patients (of whom 
42% progressed). Hence, the absolute number of 
progressive tumors in the low-risk group 1 is still 
higher than the absolute number in the high-risk 
group 3. These data indicate that changing treat­
ment and follow-up schemes based on relative 
risk alone underestimates the potential risk of the 
less-aggressive but more frequent cancers; this 
may put an equal number of patients at risk of 
late detection of progression as are found in time 
by meticulous follow-up of the high-risk patient 
group. Two factors are important to overcome 
this dilemma: (1) more accurate prognostic 
markers, and (2) a reliable tool for the monitor­
ing of bladder mucosal changes during patient 
follow-up, particularly in the less-progressive 
cancers*
Cytology methods have been used in the detec­
tion and follow-up of bladder tumors. Visual mi­
croscopic interpretation of material, however, has 
been subject to low inter- and intraobserver repro­
ducibility.7 Light-microscopic image analysis of 
cytologic material allows ploidy analysis as well as 
objective interpretation of cellular and nuclear fea­
tures reflecting malignant deformation. In earlier 
studies, the use of a quantitative cytology system 
( QUANTICYT) for bladder-wash material was de­
scribed.8"10
In the present study, the QUANTICYT system is 
tested for patients with superficial bladder carci­
noma: ( I )  for diagnostic value (whether the 
QUANTICYT score correlates with the presence of 
tumor in the bladder and (2) for its ability to pre­
dict prognosis in superficial bladder cancer.
MATERIAL AND METHODS
Pa tien ts
From October 1990 to March 1995, 4137 bladder-wash 
samples from 1412 patients in six urologic institutes (one 
academic and five nonacadem ic) were obtained. Patients di­
agnosed with a superficial (stage smaller than pT2) transi­
tional cell carcinoma of the bladder were eligible for the study. 
For each bladder-wash sample, the cystoscope findings (m ul­
tiplicity, tum or size, and  papillary or solid type lesions) were 
documented. Moreover, patient history concerning earlier tu­
mor recurrences and related treatment modalities were con­
sidered. W hen histologic samples were taken, these data were 
also entered.
The b ladder-w ash  m aterial was ob ta ined  by rinsing the 
bladder at least twice w ith  saline so lu tion , e ither th rough  
a catheter or a cystoscope. Then, 25 cc of the m ateria l was 
instantly  fixed in 25 cc of 50% ethanol con ta in ing  2% poly­
ethylene glycol (C arb ow ax ) and s to red  at 5°C. Bladder 
w ashings were always perform ed after em ptying  of the 
b ladder and prio r to intravesical m anipu la tions, instilla­
tions, and  tu m or resection. At the laboratory , the m aterial 
was cen trifuged  (2000X  for 10 m in u te s ) ,  and  the pellet 
resuspended  in Carbowax fixative. For sta in ing , the m ate­
rial was centrifuged w ith a Cytospin device (C ytosp in ,
S h and on ) on  gela tin -coated  slides, postfixed  w ith  Bohm 
fixative (85%  m ethano l, 10% buffered  form alin , 5% glacial 
acetyl acetic a c id ) ,  an d  F eu lgen  s ta ined  (5  N HC1 for 60 
m inu tes; Schiff-reagent, M erck, G erm any  for 30 m inu tes , 
b o th  at room te m p e ra tu re ) .
T h e  QUANTICYT S y s t e m
The karyom etric  analysis  was perfo rm ed  o n  the Feulgen- 
sta ined  slides using  a p e rso n a l-co m p u te r-b ased  im age an a l­
ysis system 9 (Fig. 1 ) .  O n each  slide, 50 ran do m ly  se lected  
images con ta in ing  100 to 500 nucle i w ere analyzed  after 
recording on  the h a rd  d isk  of the com puter. R ecord ing  of 
these images took 2 m in u te s  per slide. T he  50 im ages per 
slide were au tom atica lly  analyzed , w ith o u t  in te rv e n tio n  by 
the technician , in 50 to 80 m in u tes . After the  au to m atic  
analysis, the se lected  n u c le i  w ere  co n to u red  and  n u m b e re d  
in the images, thus enab ling  post-analysis  v isual verifica­
tion of the objects. L ym phocytes in  the m ateria l w ere  u sed  
as reference for 2c d eoxy ribonuc le ic  (D N A ) co n ten t.  For 
each nucleus p re sen t in  the  im ages, the  DNA c o n te n t  an d  
nuclear shape feature PASS (b ased  on  the sm o o th e d  F ree ­
m an difference cha in  co d e )  w ere  d e te rm in ed .9,10 In  each 
sample, the 2c dev ia tion  in d ex  (2 cD I)  acco rd ing  to Book­
ing et a l.u  w as calculated . B oth  features w ere u se d  to d e ­
term ine the QUANTICYT d iagnosis  as described  earlie r .9,10 
The QUANTICYT sco rin g  sp e c tru m  consis ted  o f  low  risk, 
in term edia te  risk, an d  h ig h  risk , as was earlier d e te rm in ed  
by corre la tion  w ith  h is to logy  d a ta .9,10
Because several technicians recorded and reviewed the im ­
ages, reproducibility of the karyom etric analysis was tested in 
a set of 40 samples am ong three technicians. To com pare cy­
tologic and karyometric grading, 104 samples were in ter­
preted by bo th  techniques.
In 200 of 4137 samples (5 % ) ,  QUANTICYT karyom etric 
analysis could not be perform ed because of too few urothelial 
cells (a t least 100 nuclei shou ld  be m easured) or because of 
cystitis, in w hich case the large num ber of leukocytes may 
obscure the urothelial cells.
A database was linked to the system for docum enta tion  of 
patient-related inform ation, such  as earlier treatm ents and  
histology data. This inform ation was provided by the uro lo­
gist and filled out on the application form. Finally, a report 
form with clinical patient inform ation and data concern ing  all 
samples of the patient p resent in the system was draw n
(Fig. 2 ) .
Statistical analysis w as p e rfo rm ed  u s ing  the  SPSS/PC- 
plus software. F o llow -up  resu lts  are p resen ted  app ly ing  the 
Kaplan-M eier m ethod ; for significance, the  lo g -ran k  test 
was used. M ultivariate  reg ress ion  analysis acco rd in g  to 
Cox was perform ed. Significance of a test w as a ssu m ed  
w hen  P < 0 .0 5 .
RESULTS
R e p r o d u c i b i l i t y
The correlation of analysis of nuclear profile 
area, number of analyzed nuclei per sample, nu­
clear shape (PASS), and the 2cDI was tested 
among three technicians. The correlation values 
(Pearson r) between the measurements obtained 
by the different technicians range from 0.801 to 
0.925 (P <0.01). All correlations were significant 
and larger than 0.80, except for the 2cDI. This was 
caused by the large number of samples with 2cDI 
values smaller than 1. In this group, low correla­
tion values among the measurements obtained by
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FIGURE 2. Report form with karyometric analysis results and patient data.
TABLE I. Comparison cytologic and 
karyometric analysis with actual 
tumor status (n = 104)
Cytology
Karyometric
Score
Actual Status No Tumor Tumor No Tumor Tumor
No tumor 
Tumor
9
23
6
58
13
4
7
80
low- and intermediate-risk scores were signifi­
cantly less likely to be followed by tumor pro­
gression than were high-risk-scored samples 
(Fig. 4; Table II). Of the clinical features, the 
presence of earlier bladder tumors was signifi­
cantly correlated with a higher recurrence rate 
(P <0.01, log rank) as compared with patients 
without earlier bladder cancer. In case of a lesion
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FIGURE 3. Recurrence per risk group (n -  1412).
mor grade was only initially correlated with a 
higher recurrence rate (Fig. 6 ). Data on the uni­
variate analysis of time to recurrence and pro-
detected by cystoscopy a significantly higher re- gression for clinical and QUANT1CYT scores are 
currence rate (P <0.01, log rank) was found for presented in Tables III through VI.
multiple lesions compared with solitary lesions Multivariate Cox regression analysis for the pre- 
(Fig. 5). There was no difference in recurrence diction of tumor recurrence and progression
rate between solid and papillary lesions detected showed the combination of highest grade of earlier
by cystoscopy (P >0.10, log ran k ), whereas tu- tumors and the QUANTI CYT risk group to be the
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TABLE II. Tumor recurrence and progression rates after a 
bladder-wash sample with a low-, intermediate-, or high-risk
QUANTICYT score (Q-score) (n = 1412)
^ ^ — —------ —  —  ___■— « ■ i -  ...........................  . _
_____Recurrence (Progression) Rate (%) *_____
QUANTICYT____  3 Months 6 Months 1 Year
^ __ _____ . ________  _ _ . _ _ __ ____^ ___ _ _
Low risk (n = 745) 0.54 (0.26) 2.82 (0.26) 5.50 (0.54)
Intermediate risk (n = 399) 2.75(0.50) 8.02(0.75) 12.53(1.25)
High risk (n = 268) 5.97(2.61) 13.06(4.48) 20.52(6.34)
* P <0.001, log rank test, fo r both recurrence and progression.
4>O
V
G *O
CO<0
£o>o
12 24 36
months
FIGURE 4. Progression per risk group (n =  1412),
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FIGURE 5. Recurrence rates in patients with solitary 
and multiple lesions detected by cystoscopy.
best predictors of recurrence, as well as tumor pro­
gression (Tables IV and V I).
COMMENT
Bladder--wash material proved to be superior to 
urine for routine cytology as well as for quantita­
tive analysis.14,17,18 Flow cytometric studies 
showed that ploidy analysis of bladder-wash ma­
terial is a sensitive method of tumor detec-
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FIGURE 6, Recurrence rate after a histologically 
proven bladder tumor. Recurrence rate by tumor grade.
TABLE III. Univariate analysis for the 
prediction of tumor recurrence (n = 1412)
Prognostic Factor P Value
Age 0.4321
Sex 0.3345
Multiplicity 0.0005
Tumor growth (solid/papillary) 0.0003
Highest stage of earlier tumor 0.0418
Highest grade of earlier tumor 0.0002
QUANTICYT risk group 0.0001
TABLE IV. Multivariate analysis for the 
prediction of tumor recurrence (n = 1412)
Prognostic Factor P
Highest grade of earlier tumor 
QUANTICYT risk group
0.2135 
0.3039
P Value
0.0002
0.0010
multaneous visual interpretation and selection of 
cells, Moreover, flow cytometry is not suited for 
morphometric analysis. Quantitative light micro­
scopic techniques can be used for DNA content
don,14,17,19“22 Flow cytometry does not enable si- analysis, as well as for morphometric analy-
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TABLE V. Univariate analysis for the 
prediction of tumor progression (n = 1412)
Prognostic Factor P Value
Age 0.9513
Sex 0.5962
Multiplicity 0.4098
Tumor growth (solid/papillary) 0.1085
Highest stage of earlier tumor 0.1100
Highest grade of earlier tumor 0.0437
QUANTICYT risk group 0.0001
sis.14,2^ 24 Koss’ group in Montefiore Medical Cen­
ter in New York has extensive experience with an 
image analysis system for the classification of cells 
in voided urine.7,2x26 Sensitivity of this system was 
particularly high for high-grade tumors, but low- 
grade lesions were less readily diagnosed* The cell- 
to-cell reference classification and the use of 
voided urine instead of bladder-wash material are 
two possible reasons for the low diagnostic yield.
In bladder-washing material, two nuclear fea­
tures were found in a multivariate analysis to cor­
relate with histologic tumor grade: the 2cDI and 
the mean of a nuclear shape feature (MPASS).9 
The 2cDI is a feature related to the difference of 
nuclear DNA content within a cell population.11 
When nuclear DNA content shows a high varia­
tion between nuclei in one sample (for example, 
in aneuploid or polyploid samples or in samples 
with a high percentage of S-phase or G2M-phase 
nuclei), the 2cDl value is high. Of additional pre­
dictive value to the 2cDI was the MPASS feature 
value per sample. The PASS is a nuclear shape de­
scriptor based on analysis of the smoothed Free­
man difference chain code.2' In particular, PASS is 
sensitive to elongation of the nuclear shape. Low 
MPASS values indicate more ellipsoid-shaped nu­
clei. These two nuclear features, the 2cDI and the 
MPASS, are plotted in a scattergram that allows the 
comparison of subsequent samples of the sample 
patient in one plot.
Hence, the graphic representation of several 
samples makes this method particularly suitable 
for close monitoring of changes in the bladder- 
wash cytology profile of the patient in daily prac­
tice. There have been few reports of clinically ap­
plicable karyometry systems. However, findings 
on small patient populations using the karyome- 
tric system showed that it could provide potential 
clinical information. Thus, a clinically applicable 
system for the quantitative analysis of bladder- 
wash material was designed (QUANTICYT).
The findings of the present study show that 
QUANTICYT karyometric analysis aids in pre­
dicting tumor recurrences and progression in pa­
tients with superficial bladder cancer, with either
TABLE VI. Multivariate analysis for the 
prediction of tumor progression (n = 1412)
Prognostic Factor P P Value
QUANTICYT risk group 1.4925 0.0001
Highest grade of earlier tumor 0.5055 0.0404
abnormal or normal cystoscope findings. When no 
bladder abnormalities were found with the cysto­
scope, the presence of earlier bladder cancer was 
an important prognostic clinical feature. The prog­
nostic value of prior recurrences was also found 
by Kurth et til.3 One-year recurrence rates were 3% 
in patients with low-risk QUANTICYT score and 
a primary tumor, whereas they were 34% in pa­
tients with high-risk QUANTICYT score and a his­
tory of recurrent bladder cancer. Remarkably, the 
presence of prior tumor recurrences was only of 
additional prognostic value in low- and interme- 
diate-risk samples.
Not all bladder-wash samples were obtained 
when the tumor was present in the bladder. Hence, 
a subgroup of patients in whom a tumor was re­
sected just after bladder-wash material sampling 
was studied (n = 232). Multivariate Cox regres­
sion analysis showed that tumor grade and QUAN­
TICYT risk group were the best predictors of tu­
mor recurrence in this patient group. The fact that 
QUANTICYT analysis is of prognostic value when 
done prior to transurethral tumor resection, as 
well as during follow-up, indicates that it can be a 
tool for longitudinal follow-up. Changes in 
QUANTICYT score during follow-up seem to in­
dicate alterations in the bladder mucosa that sub­
sequently influence prognosis.
In the present analysis, tumor progression 
occurred at low overall frequency (2.6% ). 
No significant difference for progression rates 
was observed between low and intermediate 
QUANTICYT risk samples. The QUANTICYT 
score of high risk was strongly correlated with tu­
mor progression. Whether the higher recurrence 
rate observed in intermediate-risk samples, as 
compared with low-risk samples, results in higher 
progression rates remains to be established by 
longer follow-up.
The false-positive rate of karyometric analysis 
during and shortly after intravesical chemotherapy 
or BCG instillations was increased compared with 
samples not taken during instillations. However, 
longer follow-up demonstrated that recurrences 
could still be predicted. In particular, aneuploidy 
was related to recurrent tumor. These data indicate 
that QUANTICYT analysis may still provide prog­
nostic information during intravesical therapy,
whereas routine cytology is considered unreliable 
in these patients.
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Cystoscopy is an important tool for follow-up in 
patients with superficial bladder cancer. Recently, 
the selection of which patients should undergo 
this invasive investigation was under analysis.6 
The identification of patients at higher risk for tu­
mor recurrence or progression was based on mul­
tiplicity and the presence of tumor recurrence at 
3 months after transurethral resection. QUANTI- 
CYT in combination with these clinical data, aids 
in defining patients at risk, and in need for fre­
quent cystoscopy. Prospective analysis of this risk 
factor-based follow-up is needed to incorporate it 
in daily routine. Whether QUANTICYT analysis 
can indicate patients likely to benefit from intra­
vesical therapy remains to be established.
CONCLUSIONS
Quantitative hght-microscopy techniques enable 
objective interpretation of nuclear shape and DNA 
content. The QUANTICYT score thus calculated 
from bladder-wash material correlates with tumor 
recurrences and progression in patients with su­
perficial bladder cancer. Overall recurrence rates 
at 1 year for the QUANTICYT scores were 5.5% 
for low-risk samples, 12.5% for intermediate risk, 
and 20.5% for high risk. Progression rates were
0.5%, 1.3%, and 6,3%, respectively. In a multi­
variate analysis, karyometric data provide signifi­
cant additional information to tumor grade for the 
prediction of tumor recurrence and progression. 
The QUANTICYT system enables monitoring of 
bladder mucosal changes in a quantitative and 
easy-to-read format. Selecting patients based on 
risk analysis may reduce the number of cystosco­
pies.
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